A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

Start Date24 Apr 2026

Sponsor / Collaborator

Almirall SA

CTIS2024-519811-32-00

/ Not yet recruitingPhase 4

An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Start Date01 Apr 2026

Sponsor / Collaborator-

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Lebrikizumab

100 Translational Medicine associated with Lebrikizumab

100 Patents (Medical) associated with Lebrikizumab

240

Literatures (Medical) associated with Lebrikizumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Li, Sitong ; Chen, Xiang ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

02 Mar 2026·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

Author: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

01 Mar 2026·JOURNAL OF DERMATOLOGY

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study

Letter

Author: Chijiwa, Chika ; Okada, Yoshiki ; Tada, Yayoi ; Suzuki, Shoya ; Hiura, Azusa ; Kamata, Masahiro ; Tomura, Yayoi ; Hayashi, Kotaro ; Watanabe, Ayu ; Tanaka, Takamitsu

179

News (Medical) associated with Lebrikizumab

20 hours ago
·www.businesswire.com

AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne

DENVER--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Phase 3 evaluations in acne. "Our goal is to bring meaningful, evidence‑based treatment options to people living with skin diseases. The breadth of data we are sharing at AAD 2026 – from long‑term results and real‑world evidence for lebrikizumab to clinically relevant AK endpoints with tirbanibulin – reflects our commitment to rigorous science, patient‑centred outcomes, and strong collaboration with dermatology partners,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer. “AAD is an important moment each year to demonstrate our dedication to advancing medical dermatology and patient care. The new data we are sharing underline the real progress made across multiple skin diseases, and our commitment to bringing dermatologists evidence that supports better decision‑making and better care for their patients,” said Paul Rittman, President & General Manager, Almirall U.S. Almirall’s presence at AAD 2026 is an important opportunity to connect with healthcare professionals, partners, and industry peers. AAD 2026 is a leading international forum for medical dermatology expertise and collaboration and takes place March 27–31 in Denver, Colorado. Addressing Unmet Needs in Medical Dermatology Dermatological diseases can exert a profound physical and emotional burden. With a portfolio spanning inflammatory and proliferative skin conditions and an expanding evidence base across both controlled and real‑world settings, Almirall continues to partner with the dermatology community to improve outcomes, experience and long‑term disease control. With over 80 years of experience in healthcare, Almirall is committed to advancing science in dermatology through continuous investment in research and development and by fostering strong partnerships with the medical and scientific communities. The company's expanding portfolio in medical dermatology, particularly its focus on advanced biologic solutions for psoriasis and atopic dermatitis, underscores its dedication to providing innovative dermatological treatments and enhancing patient outcomes. 2026 AAD Annual Meeting poster overview: Almirall and its partners will present more than 15 scientific posters across atopic dermatitis, psoriasis, actinic keratosis and acne, including: Lebrikizumab (Atopic Dermatitis) – 3 Almirall Posters + 6 Eli Lilly Posters Head, neck and face AD in patients with skin of color (ADmirable) 4 year long-term safety and efficacy (ADlong) Real-world effectiveness and advanced systemic pretreated populations (ADLIFE) Improvements in absolute endpoints in real-world settings (ADLIFE) EASI clinical responses across body regions in patients needing >16 weeks to reach EASI 75/IGA 0–1 Clinical feature improvements in skin of color Allergic rhinitis comorbidity and PREPARED‑1 study design Reasons for initiating lebrikizumab in adolescents with moderate-to-severe AD Exposure–response modelling supporting every 8 week maintenance dosing Tildrakizumab (Psoriasis) – 2 Almirall Posters + 4 Sun Pharma Posters Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study Beyond skin clearance: Tildrakizumab in moderate-to-severe psoriasis patients – 2-year POSITIVE study results Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial Real-World Tildrakizumab Effectiveness in the US by Biologic Experience and Geographic Region in the PPD CorEvitas Psoriasis Registry Real-World Tildrakizumab Persistence in the US by Biologic Experience and Insurance Coverage in the PPD CorEvitas Psoriasis Registry Regional Differences in Patient Characteristics Among US Biologic Initiators from the PPD CorEvitas Psoriasis Registry Tirbanibulin (Actinic Keratosis) – 3 Posters Efficacy beyond complete clearance: percent lesion reduction as a meaningful endpoint Efficacy, safety and tolerability of up to two 5-day treatment courses Achieving complete clearance with mild-to-moderate LSRs: pooled Phase III analysis Sarecycline (Acne) – 2 Posters Truncal acne outcomes: multinational pooled Phase 3 analysis Pooled Phase 3 results in moderate-to-severe facial acne About Klisyri (tirbanibulin) ointment, 1%: INDICATION KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Ophthalmic Adverse Reactions Klisyri may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible. Local Skin Reactions Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of Klisyri. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of Klisyri is more likely to result in irritation. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain. Click here to view: Full Prescribing Information About Seysara (sarecycline) tablets: INDICATIONS AND USAGE SEYSARA (sarecycline) tablet 60/100/150 mg, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use: Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SEYSARA is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. WARNINGS AND PRECAUTIONS Like other tetracyclines, SEYSARA can cause fetal harm when administered to a pregnant woman. If SEYSARA is used during pregnancy, or if the patient becomes pregnant while taking SEYSARA, the patient should be informed of the potential hazard to the fetus and treatment should be stopped immediately. The use of SEYSARA during tooth development (second and third trimesters of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. If Clostridium difficile Associated Diarrhea (antibiotic associated colitis) occurs, discontinue SEYSARA. Central nervous system side effects , including light-headedness, dizziness or vertigo, have been reported with tetracycline use. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery. These symptoms may disappear during therapy and may disappear when the drug is discontinued. Intracranial hypertension in adults and adolescents has been associated with the use of tetracyclines. Clinical manifestations include headache, blurred vision and papilledema. Although signs and symptoms of intracranial hypertension resolve after discontinuation of treatment, the possibility for sequelae such as visual loss that may be permanent or severe exists. Concomitant use of isotretinoin and SEYSARA should be avoided because isotretinoin, a systemic retinoid, is also known to cause intracranial hypertension. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using SEYSARA. Bacterial resistance to tetracyclines may develop in patients using SEYSARA. Because of the potential for drug-resistant bacteria to develop during the use of SEYSARA, it should only be used as indicated. As with other antibiotic preparations, use of SEYSARA may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, SEYSARA should be discontinued and appropriate therapy instituted. ADVERSE REACTIONS The most common adverse reaction (incidence ≥1%) was nausea: SEYSARA 3.1% vs placebo 2.0%. Please see full Prescribing Information. About Ilumya (tildrakizumab-asmn): INDICATION AND IMPORTANT SAFETY INFORMATION ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients. WARNINGS AND PRECAUTIONS Hypersensitivity Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. Infections ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves. Pretreatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment. Immunizations Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines. Adverse Reactions The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea. Please see full Prescribing Information. About Ebglyss (lebrikizumab-lbkz): INDICATION AND SAFETY SUMMARY EBGLYSS is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids. It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg). Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients. Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you: Have a parasitic (helminth) infection. Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS. Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Possible side effects EBGLYSS can cause serious side effects, including: Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. The most common side effects of EBGLYSS include: eye and eyelid inflammation, including redness, swelling, and itching injection site reactions shingles (herpes zoster) These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. How to take Use EBGLYSS exactly as prescribed by your healthcare provider. EBGLYSS is given as an injection under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver. If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. Learn more EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you. Content addressed for US audience only. About Almirall Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. For more information, please visit https://www.almirall.com/

Phase 3Clinical Result

23 Mar 2026
·www.fiercebiotech.com

Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear

Analysts said deepening response rates across all key endpoints were the most surprising and impressive outcomes of Apogee Therapeutics\' phase 2 eczema data .\n Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to $5.2 billion.The data come from the maintenance stage of a phase 2 trial. At the end of the induction period, Apogee re-randomized all patients in the zumilokibart cohort to receive the anti-IL-13 antibody every three or six months. After 52 weeks, 85% of patients randomized to the six-month regimen maintained the 75% improvement on the EASI symptom scale they achieved during the induction stage.At 75%, the EASI maintenance rate was lower on the three-month regimen. But Guggenheim Securities analysts said in a note to investors that both regimens performed at least as well as Eli Lilly’s Ebglyss and Sanofi and Regeneron’s Dupixent, based on cross-trial comparisons. The analysts quoted EASI-75 maintenance rates of 82% and lower for Ebglyss and 72% for Dupixent. Data on zumilokibart’s maintenance of vIGA 0/1 outcomes, which indicate clear or almost clear skin, also compared favorably to results for Ebglyss and Dupixent. Apogee reported vIGA 0/1 maintenance rates of 86% and 78%, respectively, for the three- and six-month regimens. The analysts compared the results to a rate of 54% for Dupixent and up to 77% for Ebglyss. Ebglyss was given every two or four weeks in the trial data referenced by the analysts, while Dupixent was administered every one or two weeks. While cross-trial comparisons can be unreliable, the data suggest zumilokibart can achieve at least comparable maintenance rates despite being given less frequently. The maintenance data exceeded the Guggenheim analysts’ expectations. While praising the maintenance results, the analysts said the deepening response rates across all key endpoints were the most surprising and impressive aspect of the data. The proportion of patients who had 75%, 90% and 100% improvements on the EASI scale increased between the Week 16 and Week 52 analyses. Apogee also reported deepening responses on vIGA 0/1 and on a measure of itch symptoms. The analysts said the Week 52 results look comparable to data on AbbVie’s blockbuster JAK inhibitor Rinvoq. Monotherapy trials of Dupixent and Ebglyss randomized only responders to maintenance doses, preventing direct comparisons to the vIGA data beyond the maintenance results. The analysts said there was minimal if any deepening of responses after Week 16 in a Dupixent combination trial.Encouraged by the data, the analysts said they are increasingly convinced that zumilokibart will become the first-line treatment for most eczema patients. The prediction reflects the drug candidate’s dosing schedule and its “improving” efficacy profile, the analysts said. In eczema, the analysts expect peak sales of $5.2 billion, up from $2.6 billion before the data drop. The forecast reflects the potential for zumilokibart to claim a larger share of the market than expected. The analysts see chances for Apogee to unlock more sales by moving into indications including eosinophilic esophagitis, where weekly dosing is the current standard of care.Apogee shares rose 20% to $80 when markets opened Monday from a Friday closing price of $66.04.

Clinical ResultPhase 2

23 Mar 2026
·endpoints.news

Apogee’s Phase 2 data show its eczema drug could have the convenience edge over Dupixent, Ebglyss

Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2 maintenance data highlighted the efficacy of its anti-IL-13 antibody, called zumilokibart, administered once every three months or every half a year after an induction period. Sanofi and Regeneron’s Dupixent is given every two or four weeks after an initial loading dose, while Eli Lilly’s Ebglyss is given every four weeks after several loading doses. Apogee’s stock $APGE jumped by as much as 16% before the market opened Monday. Its 52-week data showed 75% of initial zumilokibart responders maintained a 75% or more improvement in their Eczema Area and Severity Index (EASI) score with a 360 mg dose once every three months. But that figure was even higher in patients who received zumilokibart once every six months, with 85% maintaining their response. Among people who initially achieved clear or almost clear skin on a separate eczema severity scale called the Validated Investigator Global Assessment (vIGA), 86% of those dosed every three months and 78% of those dosed every six months maintained their response. Monday’s results appear to surpass Apogee’s own benchmarks for success. TD Cowen analysts said earlier this month that the company was hoping to achieve 72% maintenance on the EASI-75 and 53% maintenance on the vIGA. These figures are based on Dupixent’s maintenance data. Last year, Apogee shared topline induction data from the first part of the Phase 2 study. Those results showed almost 70% of patients experienced a minimum 75% improvement in their EASI score at 16 weeks. For the induction regimen, patients were given 720 mg zumilokibart at weeks 0 and 2, followed by 360 mg at weeks 4 and 12. The EASI scale looks at how much a patient’s disease severity has improved from baseline, while the vIGA offers an absolute measure of the clearness of their skin. Apogee said it will present full data from the first part of the Phase 2 trial at the American Academy of Dermatology Annual Meeting in Denver later this week. The biotech also expects to share results from the second part of the study, which focuses on dose optimization, in the second quarter. Apogee plans to start Phase 3 development later this year. It also believes it could launch zumilokibart in 2029. Last week, Jefferies analysts said they expect the drug to reach $1.4 billion in peak sales.

Clinical ResultPhase 2

100 Deals associated with Lebrikizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09633	Lebrikizumab	-	DB11914

R&D Status

Approved

10 top approved records.
Login
to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	European Union	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Iceland	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Liechtenstein	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Norway	Almirall SA	16 Nov 2023

Developing

10 top R&D records.
Login
to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nummular eczema	Phase 3	Germany	Almirall SA	24 Apr 2026
Nummular eczema	Phase 3	Italy	Almirall SA	24 Apr 2026
Nummular eczema	Phase 3	Spain	Almirall SA	24 Apr 2026
Nasal Polyps	Phase 3	United States	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	China	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	Japan	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	Argentina	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	Belgium	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	Bulgaria	Eli Lilly & Co.	21 Oct 2024
Nasal Polyps	Phase 3	Canada	Eli Lilly & Co.	21 Oct 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04392154 (ADjoin, Literature \| NEWS) Manual	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	103	lebrikizumab Q8W	cjgbpgemvt(jmoguuavaa) = wjenytwbwq vuwmbwvppy (todwzcdxjn, 48.3 - 75.8) View more	Positive	10 Nov 2025
				lebrikizumab Q4W	cjgbpgemvt(jmoguuavaa) = emvwvswwxe vuwmbwvppy (todwzcdxjn, 60.9 - 85.1) View more
NCT04146363 \| NCT04178967 \| NCT04392154 (ADvocate1, Pubmed \| Clin Exp Dermatol)	Phase 3	Dermatitis, Atopic	-	Lebrikizumab every 4 weeks	mjbyypacwr(nxuqfrfrgx) = johoygmonu bheppjxpdd (zogskqkexk ) View more	Positive	08 Nov 2025
				Lebrikizumab every 2 weeks	mjbyypacwr(nxuqfrfrgx) = xdmguriwne bheppjxpdd (zogskqkexk ) View more
NCT06243198 (CTgov)	Phase 1	-	24	Lebrikizumab (250 mg Lebrikizumab)	xnjvfyvaar = jnhagyimzj xvwgigziyg (nqsushjrrd, tsznovarhz - axwrvgsybp) View more	-	12 Sep 2025
				Lebrikizumab (500 mg Lebrikizumab)	xnjvfyvaar = aguzmdutqb xvwgigziyg (nqsushjrrd, rnwmiftvbe - dcualfzwhv) View more
NCT05372419 (ADmirable, Pubmed \| Am J Clin Dermatol)	Phase 3	Dermatitis, Atopic	90	Lebrikizumab 250 mg (Fitzpatrick skin phototype IV-VI + Non-White race)	pexvcjdwva(ranhkqwfxn) = jomswopwxk erqvzixule (dmdraxwuwb ) View more	Positive	01 Sep 2025
NCT04392154 (ADjoin, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	1,153	Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q4W)	gnqefxinga(kfpwfsdajj) = eoedzyrfpg bmrakcctkg (vvcjmjtztf, udqigghxbv - yvoytedbzp) View more	-	03 Aug 2025
				Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q8W)	gnqefxinga(kfpwfsdajj) = jaivdyuaxc bmrakcctkg (vvcjmjtztf, rmoexlrkeg - eaqtsamvnh) View more
NCT04392154 (ADjoin, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Moderate Atopic Dermatitis Maintenance Interleukin-13	-	Lebrikizumab 250 mg Q2W	bhtbehtmge(sxmvrwzpll) = During ADjoin, adverse events were reported by 62.2% of patients from ADvocate1&2 and ADhere who received lebrikizumab Q2W or Q4W, with the majority being mild (31.5%) or moderate (27.0%) in severity, and 2.2% leading to discontinuation due to adverse event swdxyslyer (nwmdiuoezs )	Positive	01 Aug 2025
				Lebrikizumab 250 mg Q4W
NCT06444165 (CTgov)	Phase 3	Dermatitis, Atopic	55	Lebrikizumab Pen	zlivajumte = fefnysvwah fiqiqcqsxr (edgfeaqerj, pgioxrquhe - flkqdiblvk) View more	-	29 Jul 2025
NEWS Manual	Phase 3	Dermatitis, Atopic	90	Ebglyss	jlpormrtnt(ijfovijmah) = yotwrdliqn dagflfbuhs (xptcvltlvv ) View more	Positive	22 Jul 2025
NCT05372419 (ADmirable, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	90	Lebrikizumab (Lebrikizumab 250 mg Q2W)	cqsdpluaol = tlwfjiwofb psozsdeskk (dobdjkpklu, kcwelikidw - hmdtzrlgep) View more	-	11 Jun 2025
				Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W)	srfwvijoyj = fgmjqbzslx srbslayvla (lmbskpzcuy, sotwkaxglp - yaujeiykft) View more
NCT05369403 (ADapt, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	86	Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W)	qcostbymih = sjrolpghwo gjgzetepfg (ztsoyicifx, jcyhhwjwdd - shcyzzmjwk) View more	-	19 Mar 2025
				Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q4W)	qcostbymih = dfremojrxs gjgzetepfg (ztsoyicifx, mxcecdaqjr - cptatbacwj) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

view full example data

Deal

Boost your decision using our deal data.

login

view full example data

Core Patent

Boost your research with our Core Patent data.

login

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

login

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

login

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

view full example data

AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free

Lebrikizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation